Health Care [ 12/12 ] | Biotechnology [ 67/73 ]
NASDAQ | Common Stock
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of Aramchol for the treatment of liver diseases.
It develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule for the treatment of non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus.
The company also evaluates Aramchol through ARRIVE Study for HIV-associated lipodystrophy and non-alcoholic fatty liver disease.
In addition, it develops products for cardiometabolic indications.
The company has a license agreement with Samil Pharma.
Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with Virginia Commonwealth University to investigate the effect of adding Aramchol to prevent drug resistance to standard-of-care oncology agents in the treatment of hepatoma, cholangiocarcinoma, and colorectal cancer.
Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Ramat Gan, Israel.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 28, 25 | -0.62 Increased by +36.73% | -0.89 Increased by +30.34% |
| Mar 26, 25 | -1.93 Decreased by -96.68% | - |
| Nov 20, 24 | -2.31 Decreased by -861.42% | - |
| Aug 23, 24 | -2.13 Decreased by -124.55% | - |
| May 30, 24 | -0.98 Increased by +10.09% | -0.32 Decreased by -206.25% |
| Mar 29, 24 | -0.98 Decreased by -880.00% | -0.32 Decreased by -206.25% |
| Nov 22, 23 | -0.24 Decreased by -14.29% | -0.27 Increased by +11.11% |
| Aug 9, 23 | -0.95 Decreased by -533.33% | -0.34 Decreased by -179.41% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 25 | 0.00 Decreased by N/A% | -1.10 M Increased by +13.41% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 24 | 0.00 Decreased by N/A% | -3.21 M Decreased by -59.18% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 24 | 0.00 Decreased by N/A% | -1.91 M Decreased by -29.94% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by N/A% | -1.12 M Increased by +29.76% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by N/A% | -1.27 M Increased by +23.10% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 0.00 Decreased by N/A% | -2.02 M Increased by +28.74% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -1.47 M Increased by +72.62% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -1.59 M Increased by +57.29% | Decreased by N/A% Decreased by N/A% |